Bialbix Tablets (Clopidogrel Camilsulfonate)

Adult dose

○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), start treatment on the first day with a loading dose of 300 mg of this drug once daily, followed by a maintenance dose of 75 mg orally once daily. In this case, aspirin 75 ～ 325 mg should be administered concomitantly with this drug once daily. 3. For patients with atrial fibrillation, administer 75 mg of this drug orally once daily. In this case, aspirin 75 ～ 100 mg should be administered concomitantly with this drug once daily. ○ Patients with renal impairment : Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment : Treatment experience in patients with moderate hepatic disease and bleeding diathesis is limited. This drug may be administered with or without food.

This medication may be less effective in individuals with genetically impaired CYP2C19 enzyme function. In such cases, alternative treatment methods or other medications may be necessary. Patients with allergies to this medication or its components, those with existing bleeding, patients with severely impaired liver function, and nursing mothers should not take this medication. This drug should be used cautiously in patients at high risk of bleeding, and immediate blood tests should be performed if bleeding symptoms are suspected. Patients scheduled for surgery should stop taking this medication 5 to 7 days before the operation and resume after bleeding has stopped. Care should be taken when this drug is taken with other medications that increase the risk of bleeding. Particularly, combining with aspirin may increase the risk of bleeding, so consultation with a physician is necessary. While taking this medication, watch for bleeding symptoms such as gastrointestinal bleeding, nosebleeds, bruising, hematuria. This medication inhibits platelet function in the blood, making it more challenging for blood to coagulate. Therefore, the time it takes for bleeding to stop may be longer than usual; if bleeding persists, immediate notification to healthcare personnel is required. During the use of this medication, if symptoms of infection or fever occur, testing may be necessary to consider possible bone marrow function abnormalities. During pregnancy, the safety of this medication has not been established, so it is advisable not to take it unless in special cases. If nursing, consider discontinuing breastfeeding or the medication, as it may be secreted in breast milk. The elderly or patients with impaired kidney or liver function are at higher risk of bleeding and require dosage adjustments and monitoring. Overdose may increase the risk of bleeding, requiring treatments such as platelet transfusions. This medication should be kept out of reach of children and should not be transferred to another container.

• bleeding
• gastrointestinal bleeding
• hospitalizable bleeding
• purpura
• contusion
• hematoma
• epistaxis
• hematoma
• hematuria
• intraocular bleeding

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, and it should be kept at a temperature between 1 to 30 degrees Celsius at room temperature. Storing it this way can help maintain its effectiveness for a longer time.

Appearance

Pink round film-coated tablets

Package unit

30 tablets (10 tablets/PTP x 3)